» Articles » PMID: 10084311

Influence of Increased C-Myc Expression on the Growth Characteristics of Human Melanoma

Overview
Publisher Elsevier
Specialty Dermatology
Date 1999 Mar 20
PMID 10084311
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Overexpression of the proto-oncogene c-myc has been associated with neoplastic transformation in a variety of tumors. For human melanoma high c-myc expression has been found in the vertical growth phase and higher positivity reported in metastases than primary tumors. The principle aim of this study was to determine, whether c-Myc expression influences the metastatic behavior of human melanoma in the absence of lymphocyte-mediated immune phenomena. The growth characteristics and tumor biology of two c-myc transfectants of the human melanoma cell line IGR39D, expressing c-Myc 1.7 and three times over baseline and the respective vector control were analyzed both in vitro and in a severe combined immunodeficient mouse model in vivo. Both c-myc transfectants showed increased growth rates, anchorage independent growth and directed cell movement in culture. Subcutaneously implanted IGR39D melanomas highly overexpressing c-Myc spontaneously formed macroscopic metastases (lymph nodes and lung) in severe combined immunodeficient mice in all cases (n = 7 per group), whereas less prominent c-Myc overexpression caused the development of only lung micrometastases. During the time period leading to terminal disease in animals injected with c-myc transfected human melanoma cells, melanoma development was not seen in vector controls. These findings suggest that constitutive high c-Myc expression in human melanoma results in a more aggressive growth behavior both in vitro and in vivo and favors metastasis in severe combined immunodeficient mice by factors unrelated to immune phenomena such as class I human leukocyte antigen downregulation known to be associated with c-Myc expression.

Citing Articles

Impact of coconut kernel extract on carcinogen-induced skin cancer model: Oxidative stress, C-MYC proto-oncogene and tumor formation.

Sandhya S, Talukdar J, Gogoi G, Dey K, Das B, Baishya D Heliyon. 2024; 10(8):e29385.

PMID: 38665592 PMC: 11043960. DOI: 10.1016/j.heliyon.2024.e29385.


Identification of MYC intron 2 regions that modulate expression.

Tompkins V, Xue Z, Peterson J, Rouse W, OLeary C, Moss W PLoS One. 2024; 19(1):e0296889.

PMID: 38236931 PMC: 10795982. DOI: 10.1371/journal.pone.0296889.


Reducing MYC's transcriptional footprint unveils a good prognostic gene signature in melanoma.

Zacarias-Fluck M, Masso-Valles D, Giuntini F, Gonzalez-Larreategui I, Kaur J, Casacuberta-Serra S Genes Dev. 2023; 37(7-8):303-320.

PMID: 37024284 PMC: 10153459. DOI: 10.1101/gad.350078.122.


Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached.

Wilcock D, Badrock A, Wong C, Owen R, Guerin M, Southam A Cell Rep. 2022; 39(12):110995.

PMID: 35732120 PMC: 9638004. DOI: 10.1016/j.celrep.2022.110995.


Structural recognition of the MYC promoter G-quadruplex by a quinoline derivative: insights into molecular targeting of parallel G-quadruplexes.

Dickerhoff J, Dai J, Yang D Nucleic Acids Res. 2021; 49(10):5905-5915.

PMID: 33978746 PMC: 8191789. DOI: 10.1093/nar/gkab330.